Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 8,985 followers.

Case Report: Patient With Lung Adenocarcinoma With <em>ALK-HLA-DRB1</em> Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment #lymphoma #lymsm https://t.co/HyDtEvWrBf

14 Mar 2022

Reply Repost Favourite

New research: Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment: The anaplastic lymphoma kinase (ALK) gene rearrangement… https://t.c

25 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.